Nerolidol

Nerolidol is a naturally occurring sesquiterpenoid alcohol found in the essential oils of neroli, ginger, jasmine, and cannabis, with the molecular formula C15H26O. It has been studied in preclinical settings for its interactions with lipid bilayer membranes and modulation of inflammatory signaling enzymes, though no human clinical trials currently validate these effects.

Origin & History

Nerolidol is a naturally occurring sesquiterpene alcohol (C₁₅H₂₆O) found in essential oils of numerous aromatic plants including jasmine, lavender, tea tree, cannabis, and ginger. It is extracted primarily through hydrodistillation using Clevenger-type apparatus, with yields varying from 0.12% to 80% depending on the plant source.

Historical & Cultural Context

Nerolidol has no documented traditional medical use in classical medical systems like Ayurveda or Traditional Chinese Medicine. Its historical use is limited to being a component of essential oils valued for aromatic properties in perfumery and cosmetics.

Health Benefits

• No clinically validated health benefits - all research limited to in vitro and animal studies
• Potential antimicrobial activity suggested by laboratory studies only
• Anti-inflammatory effects proposed based on preliminary cell culture research
• Antioxidant properties hypothesized from in vitro assays, not human trials
• May serve as biosynthetic precursor to vitamins E and K₁, though human relevance unknown

How It Works

Nerolidol is proposed to exert anti-inflammatory effects by inhibiting NF-κB signaling and suppressing cyclooxygenase-2 (COX-2) enzyme activity, reducing downstream prostaglandin synthesis in cell culture models. Its antimicrobial activity is attributed to its ability to intercalate into and disrupt bacterial and fungal phospholipid bilayers, increasing membrane permeability and causing cellular leakage. Antioxidant effects observed in vitro are linked to its ability to scavenge reactive oxygen species (ROS) and upregulate endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase in rodent tissue assays.

Scientific Research

No human randomized controlled trials or clinical studies have been published for nerolidol as a therapeutic agent. The compound has not been registered in ClinicalTrials.gov and no meta-analyses exist due to the complete absence of human clinical data.

Clinical Summary

No human clinical trials have been conducted on nerolidol as an isolated supplement or therapeutic agent as of 2024, making its evidence base entirely preclinical. Animal studies, primarily in rodent models, have demonstrated anti-inflammatory effects at doses of approximately 25–200 mg/kg body weight, but direct dose translation to humans is not established. In vitro antimicrobial studies have shown minimum inhibitory concentrations (MICs) against Candida albicans and Staphylococcus aureus in the range of 0.31–2.5 mg/mL, though these concentrations have not been validated in living organisms. The overall evidence strength is low, and no efficacy claims can be made for human supplementation based on current data.

Nutritional Profile

Nerolidol (C₁₅H₂₆O, MW 222.37 g/mol) is a sesquiterpene alcohol, not a nutritional food source, so traditional macronutrient/micronutrient profiling does not apply. It is a bioactive volatile compound found in trace amounts in various plant essential oils. Key details: • Chemical identity: (E)-nerolidol (trans-nerolidol) and (Z)-nerolidol (cis-nerolidol) are the two isomeric forms; (E)-nerolidol is more commonly encountered in nature. • Natural concentrations in plant sources: Found at approximately 1–30% of essential oil composition depending on species — e.g., Brassavola nodosa (~18–28% of essential oil), Myrocarpus fastigiatus (cabreuva oil, ~5–10%), neroli oil (~1–6%), Piper claussenianum (~15%), and trace amounts (<1%) in tea tree, ginger, jasmine, and lemongrass oils. • Caloric/macronutrient value: Negligible — consumed only in trace/microgram quantities via food flavoring or aromatherapy; not a source of protein, carbohydrate, fat, fiber, vitamins, or minerals in any dietary-relevant amount. • Bioactive classification: Acyclic sesquiterpene alcohol (farnesol-type); acts as a biosynthetic precursor in the mevalonate pathway, upstream of squalene, and is structurally related to farnesol and farnesyl pyrophosphate, which are precursors to vitamins E (tocopherols/tocotrienols) and K₁ (phylloquinone) in plant biosynthesis — though direct human conversion has not been demonstrated. • Lipophilicity: LogP ~4.4–5.2, indicating high lipophilicity; this contributes to strong membrane permeability and has been studied as a skin penetration enhancer for transdermal drug delivery (enhancing permeation of compounds by 2–20 fold in in vitro skin models). • Bioavailability notes: Oral bioavailability in humans is not formally characterized. Due to high lipophilicity, it is readily absorbed through skin and mucous membranes. Likely undergoes extensive first-pass hepatic metabolism (oxidation, glucuronidation) if ingested orally. GRAS (Generally Recognized As Safe) status granted by FEMA (FEMA No. 2772) for use as a food flavoring agent at very low concentrations (typically <10 ppm in food products). • No vitamins, minerals, fiber, or protein content — this is a single terpenoid compound, not a whole food.

Preparation & Dosage

No clinically established dosage exists for nerolidol in humans as human clinical trials have not been conducted. In cosmetic applications, it is typically used at concentrations below 5%. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other sesquiterpenes, essential oil compounds, farnesol, vitamin E precursors

Safety & Interactions

Nerolidol is classified as Generally Recognized As Safe (GRAS) by the FDA as a flavoring agent at the low concentrations found in food, but safety data for supplemental doses in humans is absent. Animal toxicity studies suggest a relatively high acute oral LD50 in rodents, but chronic dosing safety profiles have not been systematically established. Because nerolidol may influence CYP450 enzyme activity based on limited in vitro data, theoretical interactions with drugs metabolized by CYP3A4 or CYP2C19 cannot be ruled out. Pregnant and breastfeeding individuals should avoid supplemental nerolidol due to a complete lack of safety data in these populations.